Moderna (MRNA) Issues 2024 Shareholders Letter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Oppenheimer lifts Moderna (MRNA) rating on key 2024/2025 catalysts
January 2, 2024 8:19 AM ESTModerna (NASDAQ: MRNA) shares were raised to Outperform from Perform at Oppenheimer on Tuesday, with analyst Hartaj Singh assigning the stock a $142 per share price target.
The analyst told investors in a note that key factors for the upgrade are increasing visibility on COVID-19... More
